78 related articles for article (PubMed ID: 21809458)
21. [Effects of JAK2/STAT3 signaling pathway on angiogenesis in non-small cell lung cancer].
Zhao M; Liu F; Wang JY; Zhang WY; Gao FH; Jiang B
Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(6):375-81. PubMed ID: 21418908
[TBL] [Abstract][Full Text] [Related]
22. Nuclear Ptdlns(3,4,5)P3 signaling: an ongoing story.
Déléris P; Gayral S; Breton-Douillon M
J Cell Biochem; 2006 Jun; 98(3):469-85. PubMed ID: 16645993
[TBL] [Abstract][Full Text] [Related]
23. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
24. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Ferrajoli A; Faderl S; Van Q; Koch P; Harris D; Liu Z; Hazan-Halevy I; Wang Y; Kantarjian HM; Priebe W; Estrov Z
Cancer Res; 2007 Dec; 67(23):11291-9. PubMed ID: 18056455
[TBL] [Abstract][Full Text] [Related]
25. [Effect of losartan on expression of Janus kinase 2 and signal transducer and activator of transcription 3 in glomeruli of diabetic rats].
Shi YH; Duan HJ; He N; Wang LH; Liu QJ; Gao F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2005 Nov; 17(11):662-6. PubMed ID: 16297319
[TBL] [Abstract][Full Text] [Related]
26. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
[TBL] [Abstract][Full Text] [Related]
27. SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance.
Li J; Wu R; Yung MMH; Sun J; Li Z; Yang H; Zhang Y; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Zheng W; Wei H; Gao Y; Nemes P; Pei H; Chan DW; Li Y; Zhu W
Cell Death Dis; 2021 Apr; 12(4):341. PubMed ID: 33795649
[TBL] [Abstract][Full Text] [Related]
28. [Nuclear EGFR: a new mode of oncogenic signalling in cancer].
Gazzeri S
Biol Aujourdhui; 2018; 212(1-2):27-33. PubMed ID: 30362453
[TBL] [Abstract][Full Text] [Related]
29. JAK2 gets histone H3 rolling.
Sattler M; Griffin JD
Cancer Cell; 2009 Nov; 16(5):365-6. PubMed ID: 19878867
[TBL] [Abstract][Full Text] [Related]
30. Ajuba: An emerging signal transducer in oncogenesis.
Jia H; Peng H; Hou Z
Pharmacol Res; 2020 Jan; 151():104546. PubMed ID: 31740385
[TBL] [Abstract][Full Text] [Related]
31. Nuclear JAK2.
Dawson MA; Bannister AJ; Saunders L; Wahab OA; Liu F; Nimer SD; Levine RL; Göttgens B; Kouzarides T; Green AR
Blood; 2011 Dec; 118(26):6987-8. PubMed ID: 22194397
[No Abstract] [Full Text] [Related]
32. [Nuclear glutathione and its functions].
Kulinskiĭ VI; Kolesnichenko LS
Biomed Khim; 2010; 56(6):657-62. PubMed ID: 21395068
[TBL] [Abstract][Full Text] [Related]
33. A preliminary study of nuclear size in tissues from tumorous and nontumorous mice.
KASTEN FH
J Natl Cancer Inst; 1955 Oct; 16(2):579-89. PubMed ID: 13353791
[No Abstract] [Full Text] [Related]
34. [Studies on the nuclear structure in normal tissues and in carcinoma].
GRUNDMANN E; STEIN P
Beitr Pathol Anat; 1961; 125():54-76. PubMed ID: 13902442
[No Abstract] [Full Text] [Related]
35. Drug modulation by nuclear condensates.
Viny AD; Levine RL
Science; 2020 Jun; 368(6497):1314-1315. PubMed ID: 32554584
[No Abstract] [Full Text] [Related]
36. JAK2 activation by growth hormone and other cytokines.
Waters MJ; Brooks AJ
Biochem J; 2015 Feb; 466(1):1-11. PubMed ID: 25656053
[TBL] [Abstract][Full Text] [Related]
37. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
38. Potential JAK2 Inhibitors from Selected Natural Compounds: A Promising Approach for Complementary Therapy in Cancer Patients.
Vaziri-Amjad S; Rahgosha R; Taherkhani A
Evid Based Complement Alternat Med; 2024; 2024():1114928. PubMed ID: 38706884
[TBL] [Abstract][Full Text] [Related]
39. Pirfenidone and nintedanib attenuate pulmonary fibrosis in mice by inhibiting the expression of JAK2.
Yang Y; Wang X; Zhang J
J Thorac Dis; 2024 Feb; 16(2):1128-1140. PubMed ID: 38505034
[TBL] [Abstract][Full Text] [Related]
40. CCL5 promotes the proliferation and metastasis of bladder cancer via the JAK2/STAT3 signaling pathway.
Shen J; Chen C; Chen Z; Gong P; Lee LS; Schmeusser BN; Zhuang Q; Sun Y; Xue D; He X
Transl Androl Urol; 2023 Dec; 12(12):1845-1858. PubMed ID: 38196701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
